Ireland
--:--IST
Latest
Clinical Trials in Sweden / NCT07151222
Recruiting Observational

Role of Red Blood Cells in Cardiovascular Disease

NCT07151222 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2017-01-01
Last updated
2025-09-03

Condition(s) studied

Diabetes Mellitus

Study summary

The risk of myocardial infarction is dependent on cardiovascular risk factors including type 2 diabetes (T2D) but underlying mechanisms are poorly understood. We identified that red blood cells (RBCs) mediate beneficial cardiovascular regulatory effects under hypoxic/ischemic conditions via signaling by nitric oxide (NO) and soluble guanylate cyclase (sGC) in the RBCs. The RBCs become dysregulated in T2D which induces endothelial and cardiac injury. This project investigates the signaling of RBCs in cardiovascular disease and explores novel therapeutic strategies that target RBC function in myocardial infarction and T2D.

Aims To determine the

* mechanisms behind cardioprotective effect of RBCs in myocardial infarction
* signaling behind cardiovascular injury induced by RBCs in T2D

Work plan RBCs collected from patients with myocardial infarction, patients with T2D and healthy controls are investigated in bioassays including isolated hearts of ischemia/reperfusion, endothelial function and cell cultures. Molecular mechanisms behind the effects of RBCs are identified with focus on the NO-sGC pathway in the RBCs.

This project unravels the RBC as a mediator of cardiovascular disease and has the potential to identify novel therapeutic strategies by targeting RBC signaling.

Eligibility

Sex
ALL
Min age
25 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Type 2 diabetes Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Karolinska Institutet Stockholm Swsden Recruiting

More Karolinska Institutet trials in Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07151222 on ClinicalTrials.gov ↗ ← All trials in Sweden